Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
33.22
Nov 04 • 3:59 PM ET Dollar change+0.37 Percentage change(1.13%)
Aftermarket Close
28.88
Aftermarket • 7:58 PM ET Dollar change-4.34 Percentage change(-13.06%)
Today, 9:42 PMCaris beats Q3 2026 with EPS $0.05 vs $0.03 consensus, raises 2026 revenue outlook to $1.04–$1.05B, launches MRD and MCED platforms
Index
-
Market Cap
9.39B
Enterprise Value
9.05B
Income
105.14M
Sales
989.61M
Book/sh
2.09
Cash/sh
2.81
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
1846
IPO
Jun 18, 2025
P/E
89.23
Forward P/E
94.72
PEG
-
P/S
9.49
P/B
15.86
P/C
11.84
P/FCF
80.76
EV/EBITDA
51.99
EV/Sales
9.14
Quick Ratio
4.88
Current Ratio
5.53
Debt/Eq
0.76
LT Debt/Eq
0.75
Option/Short
Yes / Yes
EPS (ttm)
0.37
EPS next Y
0.35
EPS next Q
0.10
EPS this Y
129.56%
EPS next Y
191.34%
EPS next 5Y
-
EPS past 3/5Y
-7.57% -
Sales past 3/5Y
62.87% -
EPS Y/Y TTM
113.10%
Sales Y/Y TTM
85.37%
EPS Q/Q
99.88%
Sales Q/Q
45.38%
Insider Own
55.29%
Insider Trans
-0.58%
Inst Own
50.73%
Inst Trans
-1.64%
ROA
9.62%
ROE
20.13%
ROIC
10.13%
Gross Margin
69.66%
Oper. Margin
15.49%
Profit Margin
10.62%
SMA20
4.29%
SMA50
12.55%
SMA200
53.33%
Trades
Shs Outstand
282.58M
Shs Float
126.34M
52W High
36.50 -8.99%
52W Low
14.19 134.11%
Volatility
6.41% 6.39%
ATR (14)
1.98
RSI (14)
56.82
Beta
0.76
Rel Volume
0.85
Avg Volume
4.79M
Volume
4,093,575
Perf Week
-6.29%
Perf Month
21.00%
Perf Quarter
66.10%
Perf Half Y
73.65%
Perf YTD
23.13%
Perf Year
6.54%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
32.85
Price
33.22
Change %
1.13%
Consensus
Buy
Avg. Price Target
$32.46
Implied Upside
-2.3%
Analysts14incl. previous ratings
Rating Distribution10 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 09, 2026Initiated
UBS logoUUBS
Neutral$28-15.7%
Jun 02, 2026Resumed
WWolfe Research
Peer Perform
Apr 13, 2026Initiated
JEF logoJJefferies
Buy$28-15.7%
Apr 10, 2026Initiated
PPiper Sandler
Neutral$21-36.8%
Apr 01, 2026Initiated
GS logoGGoldman
Buy$27-18.7%
Feb 17, 2026Initiated
RRobert W. Baird
Outperform$26-21.7%
Dec 02, 2025Initiated
CCanaccord Genuity
Hold$28-15.7%
Jul 14, 2025Initiated
WWolfe Research
Outperform$32-3.7%
Jul 14, 2025Initiated
TD logoTTD Cowen
Buy$32-3.7%
Jul 14, 2025Initiated
JPM logoJJP Morgan
Overweight$31-6.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Denton John RusselSee RemarksSep 22 '26Sale31.827,500238,626174,855Sep 23 05:06 PM
JOHN RUSSEL DENTONOfficerSep 22 '26Proposed Sale31.827,500238,626Sep 22 04:08 PM
Brille Brian JSee RemarksSep 17 '26Option Exercise2.44400,000976,000630,303Sep 17 06:08 PM
Brille Brian JSee RemarksSep 17 '26Sale30.33400,00012,132,080230,303Sep 17 06:08 PM
BRIAN J BRILLEOfficerSep 17 '26Proposed Sale30.33400,00012,132,080Sep 17 04:34 PM
Spetzler David BaxleyPresidentSep 03 '26Option Exercise2.441,000,0002,440,0001,530,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 04 '26Option Exercise2.44250,000610,0001,302,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 03 '26Sale24.86478,00011,882,9901,052,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 04 '26Sale24.76119,2122,951,1171,182,871Sep 04 04:59 PM
DAVID SPETZLEROfficerSep 04 '26Proposed Sale24.76119,2122,951,117Sep 04 04:43 PM
DAVID SPETZLEROfficerSep 03 '26Proposed Sale24.86478,00011,882,984Sep 03 04:45 PM
GEORGE H POSTE REVOCABLE TRUSTFormer AffiliateAug 24 '26Proposed Sale26.06100,0002,606,320Aug 24 04:29 PM
GEORGE H POSTEDirectorAug 07 '26Proposed Sale21.4230,000642,633Aug 07 05:12 PM
GEORGE H POSTEDirectorAug 03 '26Proposed Sale16.2520,000325,000Aug 03 04:10 PM
HALBERT JONDirectorMay 15 '26Buy14.5668,000990,080704,598Jul 13 07:06 AM
Vacirca Jeff LDirectorMay 11 '26Buy16.1531,050501,42649,671May 12 08:22 AM
CASTLEMAN PETER MDirectorJan 09 '26Option Exercise18.602,50046,50018,629Jan 13 06:37 PM
Power Luke ThomasSee RemarksDec 11 '25Option Exercise2.4462,250151,890161,821Dec 12 07:39 PM
Power Luke ThomasSee RemarksDec 11 '25Sale26.5862,2501,654,46199,571Dec 12 07:39 PM
LUKE POWEROfficerDec 11 '25Proposed Sale27.1062,2501,686,975Dec 11 04:27 PM
Denton John RusselSee RemarksNov 07 '25Buy24.094,184100,7939,184Nov 10 08:12 AM
Spetzler David BaxleyPresidentNov 07 '25Buy23.854009,540460,777Nov 10 08:11 AM
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.
ChairmanDr. David Dean Halbert M.D.
Executive Vice Chairman & Executive VPMr. Brian J. Brille J.D.
M.S.Dr. David Spetzler M.B.A.
Senior VPMr. J. Russel Denton
Senior VPMr. Luke Power